Cervical Cancer Prevention
Cervical Cancer Prevention
No common cancer offers two such different routes to prevention: a vaccine that stops the infection before it starts, and a screening test that finds the precancer a decade before cancer would appear. Together they form WHO's elimination strategy — and they complement rather than replace each other.
HPV vaccination
The HPV vaccine prevents infection with the high-risk types that drive cervical cancer — and, delivered before exposure, it has already shown in national programmes that it prevents the cancer itself. Every vaccine covers types 16 and 18, responsible for about 70% of cases; the nine-valent vaccine adds 31, 33, 45, 52 and 58, raising coverage further. The same vaccine prevents the HPV-driven cancers of the anus, penis and throat in men.
Timing follows exposure, not age: the ideal window is before sexual debut, which is why WHO recommends vaccination at 9–14 years, when the immune response is also strongest. Two doses suffice under 15 in most schedules; three are used above that. But the window is not shut afterwards — vaccination is recommended well into adulthood in many countries, on the logic that any covered type not yet acquired is still prevented. What the vaccine never does is treat an infection already established or change the course of existing disease.
Screening: HPV test and cytology
Screening looks for two different things, and knowing which your test does explains a great deal. Cytology (the Pap smear) looks for abnormal cells — a lesion that already exists. HPV testing looks for the virus that causes lesions to form — a cause that is present earlier. HPV-based screening therefore catches adenocarcinoma, which arises higher in the canal and samples poorly on cytology, and it extends the safe interval, because a negative HPV test is reassuring for longer.
Many programmes combine both (co-testing); many others now use HPV testing as the primary test with cytology reserved for triage. For anyone not vaccinated or vaccinated late, screening is what carries the protection — and it works: in programmes with real coverage, the death rate from this cancer has fallen to a fraction of what it was, almost entirely through treating precancer that would otherwise have progressed.
How often to be screened
Intervals follow the test's power to reassure. A negative HPV test supports five-year intervals in most programmes; cytology alone, being less sensitive, supports three-year intervals; co-testing follows the HPV interval. Women with HIV, on immunosuppression, or with a history of treated high-grade CIN screen more often. The consistent rule across programmes is that no interval exempts a woman with symptoms — bleeding is assessed by examination whatever the calendar says.
The interval matters more than the start age in populations where screening has been delayed: the highest-yield act in this whole disease is a first screen for anyone past their mid-twenties who has never had one. From there, the programme does its work — abnormal results are followed, cleared infections return to routine intervals, and the interval itself is the protection.
After an abnormal result
An abnormal result is a fork, and the fork must be stayed on until it resolves. HPV-positive with normal cytology usually means repeat testing at a defined interval to see whether the infection clears; cytology showing low-grade changes may mean colposcopy or a repeat, depending on the programme; high-grade changes mean colposcopy with biopsy, and CIN found there is treated — by LEEP, conization or ablation — as an outpatient.
The failure mode of prevention is not the abnormal result; it is the follow-up that lapses. Treated CIN needs surveillance for years, because the risk does not return to zero when the lesion is removed. A woman treated for high-grade CIN who drops out of follow-up carries more risk than one never screened, precisely because something was found and then left unwatched. Where life moves — across cities, across countries — the records and the schedule move with the patient, which is a service international patients should confirm before they travel.
What prevention cannot do
Honesty about limits is what keeps the strategy working:
- Vaccination does not cover every type. Even nine-valent coverage leaves a minority of cancers, and vaccinated women continue screening at the standard interval.
- Screening misses and intervals lapse. A single negative test is not permanent protection; adenocarcinoma can develop between screens; and a missed appointment is the commonest way precancer becomes cancer in practice.
- Neither reverses established disease. Prevention operates before cancer exists; a diagnosis puts the treatment pathway in motion instead.
None of this weakens the case — it defines where each tool works. The vaccine works before exposure; screening works in the years-long gap between infection and cancer; treatment works after. The deaths this disease still produces are overwhelmingly in the gaps between these layers: unvaccinated, unscreened, or lost to follow-up.
A practical plan
For an individual woman, prevention reduces to three decisions with dates attached:
- Vaccinate — yourself and your children, at whatever age exposure has not yet occurred; the schedule is set with a clinician.
- Screen — know which test you are having (HPV, cytology or both) and the interval it buys; put the next date in the calendar now, not when the reminder arrives.
- Close every abnormal loop — no abnormal result ends without either clearance at a repeat test or a treated, surveilled lesion.
For patients of this hospital network, screening and colposcopy can be arranged through the international service, with reports and follow-up schedules kept across borders — the practical answer to the follow-up problem described above.